On December 18, 2024, Caiusly entered into a strategic cooperation agreement with the Advanced Institute of Clinical Medicine, Peking University (hereinafter referred to as "AICM") to co-establish the "Peking University Health Science Center - Caiusly Joint Laboratory of Organ-on-a-Chip and 3D Disease Models". Leveraging AICM’s strengths in clinical medical resources and Caiusly’s technological expertise, the joint laboratory will focus on collaborative areas including bionic microfluidic and control system R&D, 3D organoid disease model development, biological target and targeted therapy research, as well as new drug efficacy and toxicity testing. It aims to build an efficient collaborative innovation and transformation model integrating basic research, clinical research and industrialization, thereby accelerating the R&D of innovative pharmaceutical products to meet the broader market demands for precision medicine and personalized healthcare in the future.
(Photo caption: Attendees of the signing ceremony, from left to right: Wang Jiadong, Vice Director of Peking University Health Science Center; Xiao Yuan; Dong Erdan, Member of the Chinese Academy of Engineering, Director of the Peking University Cardiovascular Institute and National Key Laboratory; Wang Cunyu, Member of the U.S. National Academy of Medicine, Foreign Member of the Chinese Academy of Engineering, Dean of AICM; Qiao Jie, Member of the Chinese Academy of Engineering, Executive Vice President of Peking University and Director of Peking University Health Science Center; Han Qide, Member of the Chinese Academy of Sciences, Former Vice Chairman of the Standing Committee of the National People's Congress and the National Committee of the Chinese People's Political Consultative Conference, Former Chairman of the China Association for Science and Technology, Former Director of Peking University Health Science Center; Fu Gang, Chairman of Baheal Pharma Group; Zhang Qijun, Chairman of Caiusly; Li Lihua, Vice President of Technology at Baheal Pharma Group; Zhang Shuying, Director of the Key Account Department at Baheal Pharma Group; Wang Tao, Chief Scientist of Caiusly.)
